ABSTRACT
The COVID-19 pandemic has led to an urgent and unprecedented demand for testing – both for diagnosis and prognosis. Here we explore the potential for using sebum, collected via swabbing of a patient’s skin, as a novel sampling matrix to fulfil these requirements. In this pilot study, sebum samples were collected from 67 hospitalised patients (30 PCR positive and 37 PCR negative). Lipidomics analysis was carried out using liquid chromatography mass spectrometry. Lipid levels were found to be depressed in COVID-19 positive participants, indicative of dyslipidemia. Partial Least Squares-Discriminant Analysis (PLS-DA) modelling showed promising separation of COVID-19 positive and negative participants when comorbidities and medication were controlled for, with sensitivity of 75% and specificity of 81% in stratified subsets. Given that sebum sampling is rapid and non-invasive, this work highlights the potential of this alternative matrix for testing for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors would like to acknowledge funding from the EPSRC Impact Acceleration Account for sample collection, as well as EPSRC Fellowship Funding EP/R031118/1. Mass Spectrometry was funded under EP/P001440/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this project (IRAS project ID 155921) was obtained via the NHS Health Research Authority (REC reference: 14/LO/1221)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of support: The authors would like to acknowledge funding from the EPSRC Impact Acceleration Account for sample collection, as well as EPSRC Fellowship Funding EP/R031118/1. Mass Spectrometry was funded under EP/P001440/1.
This version revised for the inclusion of data on MS/MS validation of metabolomic features and a model change from OPLS-DA to PLS-DA.
Data Availability
This work took place as part of the COVID-19 MS Coalition and all data will be stored and fully accessible on the MS Coalition open repository.
